Skip to main content

The pharmacokinetics of epinephrine/adrenaline autoinjectors



For a century, epinephrine has been the drug of choice for acute treatment of systemic allergic reactions/anaphylaxis. For 40 years, autoinjectors have been used for the treatment of anaphylaxis. Over the last 20 years, intramuscular epinephrine injected into the thigh has been recommended for optimal effect.


To review the literature on pharmacokinetics of epinephrine autoinjectors.


Six studies assessing epinephrine autoinjector pharmacokinetics were identified. The studies, all on healthy volunteers, were completed by Simons, Edwards, Duvauchelle, Worm and Turner over the span of 2 decades. Simons et al. published two small studies that suggested that intramuscular injection was superior to subcutaneous injection. These findings were partially supported by Duvauchelle. Duvauchelle showed a proportional increase in Cmax and AUC0-20 when increasing the dose from 0.3 to 0.5 mg epinephrine intramuscularly. Turner confirmed these findings. Simons, Edwards and Duvauchelle documented the impact of epinephrine on heart rate and blood pressure. Turner confirmed a dose-dependent increase in heart rate, cardiac output and stroke volume. Based on limited data, confirmed intramuscular injections appeared to lead to faster Cmax. Two discernable Cmax’s were identified in most of the studies. We identified similarities and discrepancies in a number of variables in the aforementioned studies.


Intramuscular injection with higher doses of epinephrine appears to lead to a higher Cmax. There is a dose dependent increase in plasma concentration and AUC0-20. Most investigators found two Cmax’s with Tmax 5–10 min and 30–50 min, respectively. There is a need for conclusive trials to evaluate the differences between intramuscular and subcutaneous injections with the epinephrine delivery site confirmed with ultrasound.


Epinephrine/adrenaline is the drug of choice for treatment of systemic allergic reactions/anaphylaxis [1]. Epinephrine has been used for about a century for treatment of acute allergic reactions, and has been recommended by authorities as the first-line treatment of anaphylaxis for nearly six decades [2]. The Swedish Medical Product Agency was the first regulator to advocate the use of epinephrine in 1964. It has been recommended as first choice for treatment of anaphylaxis by academic allergy societies [3, 4]. Epinephrine has been used for the treatment of anaphylactic events in the community using prefilled syringes for six decades [5] and as epinephrine autoinjectors (EAIs) for more than four decades [6]. For two decades, epinephrine injections have been recommended to be delivered intramuscularly (IM) into the mid antero-ventral thigh [7]. The evidence for IM injection in the mid antero-ventral thigh being superior to subcutaneous injection originates from the studies by Simons et al. [8, 9]. International recommendations have been to deliver EAIs into the mid antero-ventral thigh on the preferred side for the patient [1].

The aim of this paper is to evaluate the distribution of epinephrine after injection with syringe and needle and with EAIs as the importance of intramuscular injection has been questioned recently. Also, our findings may influence the design of future autoinjectors. Data presented in five studies on epinephrine pharmacokinetics identified [8,9,10,11,12,13] are summarized in Tables 1, 2. We will review the key aspects and variables from these studies.

Table 1 Pharmacokinetic studies of epinephrine, 0.3 or 0.5 mg, and syringe and needle. Comparison of injection in the middle part of the antero-lateral (m a-l) area of the thigh
Table 2 Pharmacokinetic studies of epinephrine autoinjectors. Comparison of injection in the middle part of the antero-lateral (m a-l) or distal-ventral (d-v) area of the thigh

Selection of studies

A systematic literature search was performed in May 2020, using PubMed and the keywords “anaphylaxis” and “pharmacokinetic” and “epinephrine” and “autoinjector”. Different combinations of these search terms were used as well.

Six publications were found addressing the pharmacokinetics of epinephrine using EAIs [8,9,10,11,12, 13]. All of the papers are presented in Tables 1, 2. Sclar [14] compared Auvi-Q® and Epipen®, without publishing brand specific data. Simons et al. described the effect of injection of epinephrine by syringe and needle and by a high pressure EAI (HPEAI) Epipen®, in children in 1998 [8] and in adults in 2001 [9]. Since then, intramuscular injection in the mid antero-ventral thigh has been the general recommendation [1]. Song [15] speculated that epinephrine injection with an HPEAI into the subcutaneous tissue would propel the drug through the fascia into the muscle. This hypothesis has been supported by injection into ballistic gel. Diacono et al. [16] injected into the subcutaneous tissue of pigs. He confirmed that the fluid did not penetrate from the subcutaneous space through the fascia into the muscle, contradicting the hypothesis of Song. Duvauchelle et al. [11] published new data on the deposition of the epinephrine bolus. They visualized the location of the fluid bolus of epinephrine by ultrasound in humans. In ten of twelve obese and overweight women who received the injections with an HPEAI, Anapen®, the bolus was located in the subcutaneous tissue at the tip of the injection needle not penetrating the muscle. Recently, Worm et al. [12] reported on the pharmacokinetics and pharmacodynamics of Epipen® and syringe and needle injections in groups of women and men with different degrees of skin to muscle distance. In addition, Turner et al. [13] reported on the pharmacokinetics of epinephrine autoinjector use in adolescents at the American Academy of Allergy Asthma and Immunology Annual Meeting in 2020.

Overview of patients

The following is a summary of the patients included in the published studies.

Intramuscular injections with syringe and needle were performed in 93 patient divided into several groups: Nine children in one group [8], 66 adult men in six groups [9, 12], and 18 women divided into three groups.

In groups injected with EAIs (Table 2), there were 8 children in one group, 12 women in one group and 251 adult men were included in five groups. A total of 271 individuals with 8 to 135 individuals per group. Furthermore, three sex-mixed groups of adults with 18 females and 17 men and seven adolescent boys and five adolescent females, formed three and two groups, respectively [13].

The adult men in Simons et al. [9] study were on average obese with mean BMI 35 kg/m2. The men included by Edwards et al. [10] and Duvauchelle et al. [11] had normal weight and BMI. The women included in the trial by Duvauchelle et al. [11] were overweight or obese, BMI mean 29.7 kg/m2, range 26–34 kg/m2. Worm [12] included six men and six women with short skin to muscle distance (STMD), middle STMD and high STMD, respectively, with three different weight and BMI characteristics.

The patients included in the studies were volunteers. All of the subjects had normal heart rate, blood pressure and were not experiencing allergic reactions at the time of the studies. Importantly, in real world practice, autoinjectors are recommended for use in patients with severe systemic allergic reactions or anaphylaxis. These patients are suffering from acute allergic symptoms (shortness of breath, throat tightness) and signs (low blood pressure, wheezing, angioedema, urticaria). Epinephrine is the only readily available drug that may reverse all these changes.

In summary, the patients included in the studies performed to this time, consisted of small groups of subjects with fewer children and females. Some of the included men were obese, but most had “normal” BMI. Most female subjects were obese or overweight. All subjects were symptom-free during the studies (Tables 1, 2).

Injection site and route

Injections of epinephrine were made into the mid antero-ventral thigh, with two exceptions, Simons et al. [8], who injected children (n = 9) an individualized dose of 0.01 mg/kg body weight (mean 0.27 mg) of epinephrine with syringe and needle, or with Epipen® 0.3 mg, into an unidentified anatomical location. Duvauchelle et al. [11] intended to inject the Anapen® IM in the central inferior part of the femoralis muscle of 12 obese or overweight women. However, the men were injected in the mid antero-ventral thigh. Duvauchelle et al. [11] determined the depth of the injection bolus by ultrasonography, and found that 10/12 obese women received epinephrine subcutaneously, Fig. 1. Therefore, the red curve in Fig. 1 illustrating the plasma concentrations of epinephrine is a combination of the plasma concentrations after ten subcutaneous and two intramuscular injections, since all of the subjects did not receive subcutaneous injections. Turner et al. [13], Edwards et al. [10] and Worm et al. [12] used the mid antero-ventral thigh. Duvauchelle et al. [11] and Turner et al. [13] documented the presence of the epinephrine bolus in the intended site in the muscle by ultrasonography.

Fig. 1

Modified after Duvauchelle et al. [11]

The group mean epinephrine plasma concentrations after injection of epinephrine: Injection with syringe and 1 inch needle in normal adult men, 0.3 mg green broken line, and 0.5 mg, green line, both with Cmax1 at Tmax1 5 min. Injection with high pressure epinephrine autoinjector, Anapen®, in normal adult men, 0.3 mg black line with Cmax1 at Tmax1 5 min and in obese adult women red line with Cmax1 at Tmax1 15 min. Ten of 12 women received subcutaneous injection

Needle length

In recent years, we have published a number of papers, based on the original studies by Dr. Harold Kim’s group [17,18,19]. The aim has been to find out if present or future EAIs have the ability to deposit epinephrine in the intramuscular compartment of the vastus lateralis [20,21,22,23,24]. The outcome of these studies is that high pressure EAIs with shorter needles increase the risk of subcutaneous injection. Low pressure EAIs with longer needles are less likely to lead to subcutaneous injections due to longer needle length and are less likely to hit the bone due to less pressure required to trigger the device [23]. The length of EAI needles varies between brands and even within batches from the same manufacturer. Thick clothing increases the risk of subcutaneous injection and decreases the risk of intraosseous injection [22]. Obese individuals need longer needles (especially obese women) than the needles currently available in EAIs to reach the muscle [24]. Release of the spring of the autoinjector with low pressure on the EAI and minimal variation in approved needle length favors intramuscular injection. There are some studies supporting and others contradicting our findings. The different outcomes are likely due to minor differences in methodology.

In the Pink Book [25], the Centers for Disease Control and Prevention (CDCP) recommends a 1 to 1¼ inch (25.4–33.5 mm) needle for injection in the vastus lateralis in older children and adolescents. The recommendations of CDCP are given in Table 3. Recently, the Cochrane Database of Systematic Review recommended a 25 mm 23–25 G needle for intramuscular injection in children and adolescents [26].

Table 3 CDCP recommendations for for needle length for intramuscular injection

In their three groups, Worm et al. [12] used syringe with varying needle lengths depending on the STMD, from 12 to 40 mm, aiming at giving intramuscular injection. The other investigators probably used a 25 mm needle in their studies (Tables 1, 2).

The length of the needle of Anapen® (Duvauchelle et al. [11]) has been stated to be 10.5 mm [11]. Epipen® has an exposed needle length of 15.5 mm (5 mm variation, 13–18 mm [27]) used in the studies by Simons et al., Edwards et al. [10] and Worm et al. [12]. Emerade® 0.3 mg and 0.5 mg have a 23 mm (1.5 mm variation) long needle (Turner et al. [13]).

Pressure on the autoinjector

There are high pressure and low pressure autoinjectors. Recently, we showed that high pressure mainly compresses the muscle and not the subcutaneous tissues [28]. Therefore, low pressure on the EAI allows the use of longer needles that in turn favors intramuscular injection [23]. However, at this time there are no studies assessing serum epinephrine levels using the pressures on the probe/EAI specified by manufacturer for batch release and confirming the location of the injected bolus. In our studies, minimal pressure was applied to the ultrasound probe to mimic the pressure applied to a low pressure autoinjector, Emerade®, and about 8 lb or 35 N to the probe to mimic the pressure applied for release of the needle of high pressure EAIs (Epipen®, Jext®, Auvi-Q®, and Anapen® etc.). The low pressure is now defined as 2–8 N and the high pressure to (EpiPen®) 8.5–35 N.

Force induced by the autoinjector spring

Worm et al. [12] reported on an early Cmax, even though Epipen®, with a short needle, likely resulted in subcutaneous injections in one of their groups. They hypothesize that the strong spring of the Epipen® “may enable the propulsion of epinephrine beyond the subcutaneous fat layer or promote greater contact between the injectate and the vascular bed, resulting in a greater dispersion and systemic uptake …”. The European Medicines Agency [29], EMA, hypothesize that there will be less uptake in the subcutaneous tissue due to that possible dispersion. Worm et al. [12] did not localize the injection bolus by ultrasound as did Duvauchelle et al. [11] and Turner et al. [13]. So in the Worm et al. study, subcutaneous delivery was not confirmed but assumed on pre-injection ultrasound measurements.

Currently there are no data on the true force induced by the spring of autoinjectors. Therefore, the hypothesis of Worm et al. [12] and the EMA [29] remain speculative.

Localization of the injection bolus

The majority of data is not based on confirmed intramuscular or subcutaneous injections. Only Duvauchelle et al. [11] and Turner et al. [13] present data on the true localization of the injection bolus. And only Turner et al. [13] present group data based on only intramuscular injections. Simons injected obese men (BMI 29–64 kg/m2) with Epipen® with a 15 mm (13–18 mm) exposed needle [21]. It is likely that some (or even most) of the injections were delivered subcutaneously, since their BMI was 36.6 kg/m2 range 29–64 kg/m2. However, the injections were considered to be delivered intramuscularly in the study. Duvauchelle et al. [11] defined injections as intramuscular or subcutaneous by localizing the injection bolus by ultrasound. One man and 10/12 women intended to be given intramuscular injections were shown to, in reality, have received subcutaneous injections. Turner et al. [13] included only confirmed IM injections in the analysis [13]. Duvauchelle et al. [11] combined the data from women who received intramuscular and subcutaneous injections in the same analysis and so the same plasma level curves. This may have led to lower epinephrine Cmax levels than if all had received IM injections with similar Tmax1.

Methods for determination of plasma levels of epinephrine

The methods for determination of plasma levels of epinephrine differed between investigators and laboratories. The variation was up to 60 times between studies. For unknown reasons, the highest plasma levels of all studies were found in a group of obese males [9]. These males had five times higher levels of plasma epinephrine than small children [8] after injection of the same dose of epinephrine at 0.3 mg. The groups of Duvauchelle et al. [11], Worm et al. [12] and Edwards et al. [10] reported similar plasma levels. However, these levels were much lower than those reported by Simons et al. [8, 9]. Methods for determination of concentrations of analytes using a known analyte as standard, should obtain similar results in similar subjects. The issue of methods for determination of epinephrine in plasma will not be discussed further in this review. However, data from Simons [8, 9] and the other investigators cannot be compared in the same figures due to the significant differences in reported serum levels.

We think, in order to allow comparison between studies, all data should be reported as pg/ml [8,9,10,11,12] or nM/ml [13].

Plasma concentrations, Cmax1 and Cmax2 at Tmax1 and Tmax2

The plasma levels were measured at short intervals for 3 h by Simons et al. [8, 9] and Turner et al. [13] and for 6 h by Edwards et al. [30], Duvauchelle et al. [11], and Worm et al. [12].

The plasma concentration of epinephrine usually showed two peaks (Cmax) that are denoted as Cmax1 and Cmax2 at the times Tmax1 and Tmax2. Worm et al. [12] reported one Cmax. However, on reviewing the majority of the serum level curves, there are normally two peaks. The mean plasma epinephrine curves that included data from all individuals in a group who may have quite different absorption due to different injection sites (subcutaneous and IM) are flattened and Cmax is even eradicated. This was seen in the group of adult obese men (BMI 29–65) injected by Simons et al. with 0.3 mg of epinephrine with syringe and needle [9]. Since the majority of groups had two group Cmax, we assume two Cmax is the normal response to epinephrine injection in the subcutaneous and IM tissue. The reason for two Cmax may be initial absorption, then vasoconstriction induced by epinephrine and then Cmax2 that occurs after increased absorption after vasodilatation. The Cmax1 was lower than the Cmax2 in most studies.

All data are presented as group mean data, with standard deviations and/or ranges. No data for individual subjects are presented, except for the number of children [8] injected subcutaneously and intramuscularly with 0.3 mg epinephrine.

Tmax1 at 5 min was obtained in 2/9 children who received subcutaneous injections and in 6/8 children who received an intramuscular injection. Those injected intramuscularly had a Tmax1 of subcutaneously had a mean Tmax1 of 34 min, range 5–120 min. To understand the kinetics, inspection of individual data and confirmation of the site of the injection bolus is needed.

All groups had a mean Tmax1 that varied between studies and groups. The constructed mean curves typically demonstrated a mean Tmax1 at 5 min. Only Edwards et al. [10] report on the individual variation in Tmax1 (Table 4). Many patients had a Tmax1 more than 30 min. This may have been due to subcutaneous injections. It has been shown that Epipen® and Auvi-Q® have a high risk of subcutaneous injection and the location of the epinephrine injections were not documented in this study. Furthermore, Worm et al. [12] injected individuals with a skin to muscle distance, STMD, more than 15.5 mm with Epipen® with 15.5 mm needle. Therefore, it is possible that many injections were given SC.

There was a second Tmax, Tmax2, that occurred 20–50 min after injection. In most cases the Cmax2 peak was extracted from the figures of the papers (Fig. 1). In the study by Simons et al. in adult men [9], the Tmax2 was not present when epinephrine was injected by syringe and needle, but present after injection with Epipen®, possibly due to varying individual Tmax2 in each individual leading to a flattened curve without a clear Tmax2. The Cmax2 was not obvious in this same trial [9]. Worm et al. [12], report on Cmax. From their group curves, there is no clear Cmax1. This may be due to measurements not taken frequently enough to identify this early peak. We suggest that the frequency of epinephrine measurements be taken in a similar manner in the first 30–60 min as completed by Duvauchelle [11]. The Tmax of their reported Cmax was often 30 to even 60 min, indicating they have identified the Cmax2, Table 3. Worm et al. [12], presented their data in a method that makes it difficult to interpret. They showed the most variation in plasma epinephrine level occur within the first 5–15 min after injection compared to other studies. Duvauchelle et al. [11] used a more detailed presentation of the variation during the first hour that allows easier interpretation.

Area under the curve

The area under the curve, AUC, was determined in three ways: AUC0-20 min (AUC during the first 20 min), AUC0-t (AUC from injection to last determination of the plasma level), and AUC0-inf (AUC to infinity). AUC0-inf was calculated to the theoretical end of epinephrine plasma concentration above the background levels.

The area under the curve was estimated by all authors. Simons et al. determined the AUC only in children [8] and only as AUCinf.

Edwards et al. [30] and Duvauchelle et al. [11] had similar AUCinf, 500 times lower than those of Simons et al. [8, 9], with a mean plasma level between 200 and 700 pg/ml, with pronounced inter-individual variation. Furthermore, Duvauchelle et al. [11] reported on AUC0–20 min and Edwards et al. [30] on the AUC0-t. EAIs are indicated in subjects with the risk of immediate, severe, systemic allergic reactions. The most severe cases show life-threatening symptoms within minutes after exposure to the allergen(s). Therefore, we hypothesize, AUC0–5 min (AUC from injection to 5 min), AUCmax5 or AUC0-10 would be the most important indirect indicator of efficacy when assessing serum levels. Overall, the AUC0–20 min is the best estimate of AUC that was presented in this group of studies. However, AUC0–20 min was only about 10% of the AUCinf for the studies where data was available. No authors measured the AUC to the Cmax1 or the AUC0–5 min.

Group means

The publications by Simons et al. [8, 9], Duvauchelle et al. [11] and Edwards et al., [10] present figures with group data. When there was no patient level data on the group Cmax in the text or tables in the studies, the data presented in this paper in Tables 1, 2, have been extracted from the figures of the original publications [8,9,10,11, 12, 13]. This is indicated with question marks in Tables 1, 2 to note some aspect of uncertainty.

Using group means as the only method of analysis may introduce major issues when analyzing the plasma levels. Individual data is preferred because variable results from individuals may eradicate or neutralize each other flattening or moving the Cmax1 and 2. Thus, an injection intended to be intramuscular that is given subcutaneously, or the opposite, may influence the serum levels flattening any peak that is expected with Cmax1 or 2. One possible example is the study by Simons et al. In the pediatric study, Simons et al. [8] found the Tmax1 after injection with syringe and needle to be 34 min. This relatively late Tmax1 may have occurred in this study due to some of the participants having a Tmax1 of up to 120 min (range 5–120 min). With a large range in Tmax1, the Cmax1 may be blunted. The Tmax in this study is not comparable to the Tmax noted in the other studies reviewed in this paper. It is possible that the Tmax reported by Simons et al. may actually have been the Tmax2. We believe that only inspection of the original individual patient data, and or repetition of the experiments, can resolve this issue. Two of nine children who received subcutaneous injection had a Tmax1 of 5 min. That means that some children who were documented to be injected subcutaneously had a rapid absorption. The absorption was as rapid as in six children in the group who received injection with Epipen® with a Tmax1 of 5 min. It is not clear if this rapid absorption was due to intramuscular injection or whether subcutaneous absorption occurred as rapidly as intramuscular.

In the study in adult men by Simons et al. [9] there was one Tmax in the group injected with syringe and needle, but two Tmax after five and forty minutes in those who had received injection with Epipen®. Tmax1 and 2 are both present in all the group-based curves presented by Duvauchelle et al. [11] and Edwards et al. [10]. The most probable reason for the lack of two Tmax is that, in the study of Simons et al. [9] is that some injections with Epipen® were not given intramuscularly but subcutaneously [21, 24]. This may have led to flatting of the plasma concentration curve (see above).

Today, we know that especially obese subjects have a high risk receiving subcutaneous injections when using Epipen® [24]. In the group of adult men used by Simons et al. in 2001 [9], BMI was very high, maximum 65 kg/m2, and the weight was up to 114 kg (249 lb). In our previous paper on the influence of BMI on the risk for subcutaneous injection, we found that the majority of obese adults and many over-weight and normal-weight adults have the risk of subcutaneous injection using Epipen® or Auvi-Q® [24].

Adult men [9] weighing about three times more than the children showed six times higher plasma concentration than the children did [8, 9]. This is despite volumes of distribution that must be much larger in adult men. These higher plasma levels were unexpected findings when reviewing the results of the studies. Since the data by Simons et al. were different in the two trials, much higher than the plasma levels found by Edwards et al. [10], Duvauchelle et al. [11], and Worm et al. [12] and not presented in a way that made it possible to easily extract individual patient data, we refer the reader to the original articles [8, 9].

Duvauchelle et al. [11] performed ultrasound localization of the bolus after injection with Anapen®. They found that 10/12 women received a subcutaneous injection rather than the intended intramuscular injection.The EAI used, Anapen®, has a short needle length (mean needle length 10.5 mm). Using Anapen® 0.3 mg, Cmax1 had a Tmax1 of 15 min, as opposed to the injections of the same amount of epinephrine with a syringe with 1-inch (25.4 mm) needle that had a Tmax1 after 5 min (Fig. 1). Immediate injection of epinephrine is important for improving the clinical outcomes in anaphylaxis. It is more likely that obese women similar to those in the study by Duvauchelle et al. [11], have a high risk of subcutaneous injection even with Epipen® [24], The difference in Tmax1 may explain why obese women, with rapidly progressing symptoms, are more likely to die from anaphylaxis even when an EAI with shorter needle length and lower dose is given [31,32,33,34,35]. Actually, Pumphrey reported that [32] the autopsy of a young girl, who died from anaphylaxis, despite two Epipen® injections showed that the puncture needle channel was 16 mm, the distance from skin to muscle 22 mm. Duvauchelle et al. [11] and Turner et al. [13] used ultrasound to confirm injection into the IM space.

Duvauchelle et al. [11] and Turner et al. [13] showed that increasing the dose of epinephrine from 0.3 mg to 0.5 mg increased the Cmax1 and Cmax2 (Fig. 1). Duvauchelle et al. [11] showed that even the AUC0-20 and the AUCinf increased proportionally.

Edwards et al. [10] grouped Auvi-Q® and Epipen® data separately to compare the two brands. This study showed two Tmax at approximately five and 30 min with Cmax1 and Cmax2 about 500 and 300 pg/ml, respectively. The AUC was similar for both brands and also similar to that of Duvauchelle et al. [11]. All but one experiment used the same amount of epinephrine, 0.3 mg, Auvi-Q® and Epipen® showed similar group mean curves and Auvi-Q® and Epipen® have the same needle length. Since Edwards et al. did not document the site of the epinephrine bolus our hypothesis is that the Tmax1 reported in Table 3 in some cases were due to subcutaneous injection. The mean curves by Edwards [10] appear smooth, but are probably blunted by some individuals with very late Cmax (Tables 1, 2 and 4) due to the subjects in the study likely receiving subcutaneous injections.

In summary, group means when assessing epinephrine serum levels are somewhat misleading because there is large inter-individual variation in epinephrine absorption causing eradication or flattening of the group plasma concentration curves. This likely occurs in most published studies because the site of the epinephrine bolus is not documented to be intramuscular or subcutaneous. Only Duvauchelle et al. [11] and Turner et al. [13] present data from definite intramuscular or subcutaneous injections of epinephrine.

Table 4 The number of patients (%) with Cmax1 after different Tmax1

Summary of findings of the studies

Based on two landmark studies, Simons et al. [8, 9] proposed that intramuscular injection is superior to subcutaneous injection two decades ago. However, the data published by that group does not fully support this conclusion. Chawdbury and Meyer identified some of the potential flaws from these studies as we have identified above [36]. But they did not highlight the unexplained discrepancies in plasma epinephrine concentrations. The significant difference between the subcutaneous groups and the presumed intramuscular groups (Epipen®) may have occurred due to the variability in absorption of a few patients with very long Tmax1. Even the inter-individual variation in absorption and distribution may have influenced the lack of a Cmax2 after injection with syringe and needle. Furthermore, adult men weighing about three times more than the children showed six times higher plasma concentration than the children showed. For these reasons, in retrospect, the conclusions from Simons et al. [8, 9] studies are questionable.

Edwards et al. [10] compared two brands of EAIs with similar needle length and the same dose of epinephrine, showing similar group mean plasma levels Tmax and Cmax. This study showed that the devices for these products lead to similar delivery of epinephrine. However, we cannot confirm that the epinephrine was delivered to the IM or subcutaneous tissues. Therefore, the data cannot be used to contribute to our understanding of the pharmacokinetics of autoinjector delivered epinephrine.

The hypothesis of Simons et al. [8, 9] that intramuscular injection causes a more rapid absorption than does subcutaneous injection was partially supported by Duvauchelle et al. [11]. They also showed that after injection with an autoinjector with an inadequately short needle length for IM delivery, the bolus remains at the tip of the injection needle in the subcutaneous tissue and does not propel through the fascia into the muscle. Furthermore, Duvauchelle et al. [11] showed that increasing the injected dose, from 0.3 to 0.5 mg, increased the Cmax1, the Cmax2 and the AUC0-20, proportionally.

Turner et al. [13] confirmed that increasing the dose from 0.3 to 0.5 mg of epinephrine and using an adequate needle length for IM delivery, increased the plasma levels of epinephrine and the AUC significantly. The confirmed increased physiologic changes with the higher dose of epinephrine may be clinically important in the treatment of anaphylaxis. However, in the data presented by Worm et al. [12], the epinephrine levels were measured less frequently than the Duvauchelle [11] paper in the first 10–15 min after the injection which makes it difficult to document as accurate Cmax1/Tmax1.

Practical use of EAIs

The aim for the use of EAIs is to be injected as soon as early signs and symptoms of anaphylaxis appear. Therefore, any improvement of the function and pharmacokinetics of the EAI is of questionable value if it is not injected immediately when required. The patient can be alone or with their family, at school or with friends. Many of these people are not likely going to be familiar with the use of EAIs and will often be afraid of giving injections. The European Medicines Agency, EMA, prescribes that all companies should offer EAI training devices to improve adherence with EAI use. However, the training devices still do not reduce the fear of the real needle injection. In the USA, schools are obliged to keep an EAI available. If all adults and school children with a risk for serious systemic allergic reactions/anaphylaxis were to inject themselves with an active EAI (short needle and low dose), the proper use of EAIs may improve when true anaphylaxis occurs [37,38,39]. Another setting where patients can be trained or encouraged to use a live EAI is by having patients use live EAIs for epinephrine injection during reactions to oral food challenges.

Intramuscular or subcutaneous injection?

Twenty years ago, Simons et al. concluded that intramuscular injection of epinephrine was superior to subcutaneous injection, due a significantly higher Cmax1 with IM injection. But as noted above, the true location of the injections in those studies were not confirmed. Recently, Duvauchelle et al. [11] showed that non-intended subcutaneous injection in women caused a non-significantly slower distribution than did intramuscular injection in men. In another recent study, Worm et al. [12] found paradoxically that injection, probably subcutaneous, led to a more rapid plasma concentration increase than intramuscular injection. The Turner et al. [13] study did not compare subcutaneous and intramuscular injection. Also, in migraine therapy, investigators actually prefer subcutaneous injection, using autoinjectors with short needles that require low pressure for spring release [40, 41]. The superiority of intramuscular over subcutaneous injection of EAIs has not been absolutely confirmed with epinephrine injections.

Therefore, it is essential to investigate the pharmacokinetics of epinephrine delivered in the muscle and the subcutaneous tissue using syringe and needle to confirm if intramuscular or subcutaneous injection is preferred.

EAI studies during anaphylaxis

There are no randomized studies assessing epinephrine response during anaphylaxis episodes. Very little is known of the pharmacokinetics of epinephrine therapy during anaphylaxis. For ethical reasons, it is not possible to cause anaphylaxis in volunteers to study epinephrine responses. Recently, Moss et al. [42] proposed to study the impact of epinephrine on anaphylaxis in patients voluntarily participating in double blind, placebo controlled food challenges who have reactions. We suggest that patients participating in subcutaneous immunotherapy studies, receiving subcutaneous immunotherapy clinically, and patients receiving allergen provocation tests could be included in epinephrine studies as well.


In conclusion, on reviewing the published data, intramuscular injection of epinephrine causes a Cmax1 with Tmax1 at approximately 5 min and a Cmax2 with Tmax2 after 30–50 min. Subcutaneous injection of epinephrine leads to a Cmax1 with Tmax1 about 15 min post injection as well as a Cmax2. This data supports that intramuscular delivery of epinephrine may be more effective than subcutaneous injections. But we believe that confirmatory pharmacokinetic studies should be performed with syringe and needle assuring injections of epinephrine into the intramuscular vs. subcutaneous tissues is necessary. The ultrasound localization of the bolus is essential to confirm proper and accurate delivery of the drug. Optimally, these studies should be completed while subjects are having allergic reactions. EAIs should be studied in a similar manner.

Finally, before new EAIs are developed, the validity of data documenting the need for intramuscular versus subcutaneous injection comparing different doses of epinephrine should be studied by independent researchers.

Availability of data and materials

Not applicable.


  1. 1.

    Simons FE, Ardusso LR, Bilo MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Org J. 2014;7(1):9.

    Article  Google Scholar 

  2. 2.

    Engel A, Bolin, Lindgren S, Ström G, Colldahl H, Gordh T, et al. Angående behandling av överkäslighetsreaktioner (Regarding the treatment of hypersensitivity reactions) Stockholm: Kungliga Medicinalstyrelsen (Royal Medical Council); 1964. p. 1–3.

  3. 3.

    Kemp SF, Lockey RF, Simons FE, World Allergy Organization ad hoc Committee on Epinephrine in A. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. 2008;63(8):1061–70.

    CAS  Article  Google Scholar 

  4. 4.

    Muraro A, Roberts G, Worm M, Bilo MB, Brockow K, Fernandez Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–45.

    CAS  Article  Google Scholar 

  5. 5.

    Peck GA. Insect sting anaphylaxis. Calif Med. 1963;99:166–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Lockey SD. A new method of administering aqueous epinephrine: the EpiPen, an automatic syringe. J Asthma Res. 1980;17(4):153–5.

    CAS  Article  Google Scholar 

  7. 7.

    Joint Task Force on Practice P, American Academy of Allergy A, Immunology, American College of Allergy A, Immunology, Joint Council of Allergy A, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3 Suppl 2):S483–523.

    Google Scholar 

  8. 8.

    Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998;101(1 Pt 1):33–7.

    CAS  Article  Google Scholar 

  9. 9.

    Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108(5):871–3.

    CAS  Article  Google Scholar 

  10. 10.

    Edwards ES, Gunn R, Simons ER, Carr K, Chinchilli VM, Painter G, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol. 2013;111(2):132–7.

    CAS  Article  Google Scholar 

  11. 11.

    Duvauchelle T, Robert P, Donazzolo Y, Loyau S, Orlandini B, Lehert P, et al. Bioavailability and cardiovascular effects of adrenaline administered by anapen autoinjector in healthy volunteers. J Allergy Clin Immunol Pract. 2018;6(4):1257–63.

    Article  Google Scholar 

  12. 12.

    Worm M, Nguyen D, Rackley R, Muraro A, Du Toit G, Lawrence T, et al. Epinephrine delivery via EpiPen((R)) Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. Clin Transl Allergy. 2020;10:21.

    CAS  Article  Google Scholar 

  13. 13.

    Turner PJ, Patel N, Isaacs E, Duca B, Muhamed H, Nagratnam N, et al. Safety and pharmacokinetics of 0.3 mg/0.5 mg Epinephrine injection by autoinjector in food-allergic teen-agers: a randomized, cross-over trial. J Allergy Clin Immunol. 2020(2).

  14. 14.

    Sclar DA. Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery. Ther Clin Risk Manag. 2013;9:149–51.

    CAS  Article  Google Scholar 

  15. 15.

    Song TT. Epinephrine autoinjectors: compression and propulsion do have a role in delivery depth. J Allergy Clin Immunol Pract. 2015;3(5):827–8.

    Article  Google Scholar 

  16. 16.

    Diacono D, Pumphrey RS, Sharma V, Arkwright PD. The deep fascia of the thigh forms an impenetrable barrier to fluid injected subcutaneously by autoinjectors. J Allergy Clin Immunol Pract. 2015;3(2):297–9.

    Article  Google Scholar 

  17. 17.

    Tsai G, Kim L, Nevis IF, Dominic A, Potts R, Chiu J, et al. Auto-injector needle length may be inadequate to deliver epinephrine intramuscularly in women with confirmed food allergy. Allergy Asthma Clin Immunol. 2014;10(1):39.

    Article  Google Scholar 

  18. 18.

    Kim L, Nevis IF, Tsai G, Dominic A, Potts R, Chiu J, et al. Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone. Allergy Asthma Clin Immunol. 2014;10(1):40.

    CAS  Article  Google Scholar 

  19. 19.

    Dreborg S, Wen X, Kim L, Tsai G, Nevis I, Potts R, et al. Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy? Allergy Asthma Clin Immunol. 2016;12:11.

    Article  Google Scholar 

  20. 20.

    Dreborg S, Kim L, Tsai G, Kim H. Epinephrine auto-injector needle lengths: Can both subcutaneous and periosteal/intraosseous injection be avoided? Ann Allergy Asthma Immunol. 2018;120(6):648–53.

    Article  Google Scholar 

  21. 21.

    Dreborg S, Tsai G, Kim H. Implications of variation of epinephrine auto-injector needle length. Ann Allergy Asthma Immunol. 2019;123(1):89–94.

    Article  Google Scholar 

  22. 22.

    Dreborg S, Tsai G, Kim H. Epinephrine auto-injector needle length. The impact of winter clothing. Allergy Asthma Clin Immunol. 2020;16:1–8.

    Article  Google Scholar 

  23. 23.

    Dreborg S, Kim H. Determination of suitable needle length for new epinephrine auto injectors. J Allerg Res. 2020;2(1):56–61.

    Google Scholar 

  24. 24.

    Dreborg S, Tsai G, Kim H. Epinephrine auto-injector needles Does height and BMI add valuable information in adults. Global J Immunol Allergic Dis. 2020;7:6–19.

    Google Scholar 

  25. 25.

    Hamborsky J, Kroger A, Wolfe S, editors. The pink book, epidemiology and prevention of vaccin-preventable diseases. 13th ed. Washington: Centers for Disease Control and Prevention, Public Health Foundation; 2015. p. 79–106.

    Google Scholar 

  26. 26.

    Beirne PV, Hennessy S, Cadogan SL, Shiely F, Fitzgerald T, MacLeod F. Needle size for vaccination procedures in children and adolescents (Review). Oxford: The Cochrane Collaboration; 2018.

    Google Scholar 

  27. 27.

    Dreborg S, Kim H. Authors’ response. Anna Allergy Asthma Immunol. 2018;121(5):644–5.

    Article  Google Scholar 

  28. 28.

    Dreborg S, Kim H. Tissue compression and epinephrine deposition. J Allergy Clin Immunol Pract. 2019;7(6):2096–7.

    Article  Google Scholar 

  29. 29.

    Assessment report Referral under Article 31 of Directive 2001/83/EC Adrenaline auto-injectors (AAIs). London: European Medicines Agency, EMA/478468/2015 Committee for Medicinal Products for Human Use (CHMP) 2015. p. 1–2.

  30. 30.

    Edwards ES. Bioavailability of Auvi-Q and EpiPen: focus on pharmacokinetics. Clin Pediatr. 2013;52(9):890.

    Article  Google Scholar 

  31. 31.

    Inquiring into the death touching Poppy Harway, Summing up: Hearing before the HM Coroner’s Court, Ipswich, H.M. Coroner’s Court, Ipswich(June 28th, 2011, 2011).

  32. 32.

    Pumphrey RSH. Autopsy of Poppy Harvey. 2014.

  33. 33.

    Bloom D. Coroner Presiding Over Pret A Manger Inquest Slams EpiPen as “Inherently Unsafe”:; 2018 [Available from:

  34. 34.

    Gowland MH, Walker MJ. Food allergy, a summary of eight cases in the UK criminal and civil courts: effective last resort for vulnerable consumers? J Sci Food Agric. 2015;95(10):1979–90.

    CAS  Article  Google Scholar 

  35. 35.

    Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy Asthma Clin Immunol. 2014;10(1):38.

    Article  Google Scholar 

  36. 36.

    Chowdhury BA, Meyer RJ. Intramuscular versus subcutaneous injection of epinephrine in the treatment of anaphylaxis. J Allergy Clin Immunol. 2002;109(4):720 author reply-1.

    Article  Google Scholar 

  37. 37.

    Hellstrom A, Eriksson K, Efraimsson EO, Svedmyr J, Borres MP. Assessment of self-administered epinephrine during a training session. Acta Paediatr. 2011;100(7):e34–5.

    Article  Google Scholar 

  38. 38.

    Dreborg S. Epinephrine auto-injectors: information, education, training and acceptance. Allergol Immunopathol. 2020;48(1):1–2.

    CAS  Article  Google Scholar 

  39. 39.

    Dreborg S. When should adrenaline be given and by whom? Pediatr Allergy Immunol. 2013;24(1):97–8.

    Article  Google Scholar 

  40. 40.

    Collins DS, Kourtis LC, Thyagarajapuram NR, Sirkar R, Kapur S, Harrison MW, et al. Optimizing the bioavailability of subcutaneously administered biotherapeutics through mechanochemical drivers. Pharm Res. 2017;34(10):2000–11.

    CAS  Article  Google Scholar 

  41. 41.

    Jones GB, Collins DS, Harrison MW, Thyagarajapuram NR, Wright JM. Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med. 2017;9(405):eaaf9166.

    Article  Google Scholar 

  42. 42.

    Moss J, Jani Y, Edwards B, Tomlin S, Rashed AN. Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto-injector for anaphylactic reactions: a review of literature. Br J Clin Pharmacol. 2020.

    Article  PubMed  Google Scholar 

Download references


Not applicable.


Open Access funding provided by Uppsala University.

Author information




SD outlined the paper and wrote the first version. Both HK and SD discussed and modified the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Sten Dreborg.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Harold Kim as well as Sten Dreborg have approved the final, submitted version.

Competing interests

Sten Dreborg has been consultant to Bausch & Lomb. Harold Kim has been on the advisory boards for Bausch Health, Kaleo and Pfizer.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dreborg, S., Kim, H. The pharmacokinetics of epinephrine/adrenaline autoinjectors. Allergy Asthma Clin Immunol 17, 25 (2021).

Download citation


  • Epinephrine
  • Autoinjector
  • Pre-filled syringe
  • Pharmacokinetics
  • Tmax
  • Cmax
  • Intramuscular
  • Subcutaneous
  • Area under the curve (AUC)